Gonadotropin, Chorionic

Summary

Gonadotropin, Chorionic (CHEMBL1201509) is an approved protein (ATC G03GA01) targeting GNRHR and GNRHR2; indicated across 11 conditions including infertility disorder and polycystic ovary syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: G03GA01
• Targets: 2 (GNRHR, GNRHR2)
• Indications: 11 conditions
• Clinical trials: 39

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201509
Name	Gonadotropin, Chorionic
Type	Protein
Max phase	4
ATC	G03GA01

Also known as: Choragon, Choriogonadotropin beta, Choriogonadotropine beta, Chorionic gonadotrophin, Chorionic gonadotropin, Coriogonadotropina beta, Equine chorionic gonadotropin, Gonadotraphon lh, Gonadotrofina corionica, Gonadotrophine chorionique, Gonadotropin, chorionic

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GNRHR	GnRH1 receptor	Full agonist	10	0.1%	P30968
GNRHR2	GnRH2 receptor	Full agonist	7.37		Q96P88

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 2 target gene(s): GNRHR, GNRHR2.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Hormone ligand-binding receptors	2	GNRHR, GNRHR2
G alpha (q) signalling events	2	GNRHR, GNRHR2

Dominant GO biological processes

GO term	Targets
G protein-coupled receptor signaling pathway	2
cellular response to hormone stimulus	2
gonadotropin secretion	1
signal transduction	1
cellular response to gonadotropin-releasing hormone	1

Indications & clinical

Indications

11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
infertility disorder	3	MONDO:0005047	EFO:0000545
polycystic ovary syndrome	3	MONDO:0008487	EFO:0000660
hypogonadism	3	MONDO:0002146	MONDO:0002146
breast neoplasm	3	MONDO:0021100	MONDO:0007254
Klinefelter syndrome	3	MONDO:0006823	EFO:1001006
spermatogenic failure	2	MONDO:0004983	EFO:0000279
anovulation	2	MONDO:0002775	MONDO:0002775
gonadal disorder	1	MONDO:0002259	MONDO:0002259
graft versus host disease	1	MONDO:0013730	EFO:0004599

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 39.

Phase distribution

Phase	Trials
PHASE4	16
Not specified	15
PHASE3	4
PHASE1	2
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00415792	PHASE4	UNKNOWN	Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs
NCT00627406	PHASE4	COMPLETED	Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles
NCT00750100	PHASE4	COMPLETED	Low Dose hCG in the Late Follicular Phase
NCT00844311	PHASE4	COMPLETED	Supplementation With Human Chorionic Gonadotropin (hCG) During Controlled Ovarian Stimulation With Recombinant Follicle-stimulating Hormone (FSH) for In Vitro Fertilisation
NCT00870025	PHASE4	COMPLETED	Human Chorionic Gonadotropin (hCG) Priming Prior to Controlled Ovarian Hyperstimulation (COH) in Poor Responder In Vitro Fertilization (IVF) Patients
NCT01607203	PHASE4	COMPLETED	Trial Comparing hCG Triggering Versus hCG Associated With GnRH Agonist
NCT01888744	PHASE4	COMPLETED	Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist
NCT02310074	PHASE4	UNKNOWN	Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism
NCT02397551	PHASE4	COMPLETED	Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day
NCT02703584	PHASE4	COMPLETED	Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation
NCT02880280	PHASE4	UNKNOWN	Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism
NCT03115320	PHASE4	TERMINATED	Frozen-thawed Embryo Transfer in a Natural Cycle: hCG Triggering Versus LH Home Test
NCT03687606	PHASE4	UNKNOWN	Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH)
NCT04008966	PHASE4	COMPLETED	Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles
NCT04997525	PHASE4	COMPLETED	Estradiol and Progesterone Levels Following Frozen Embryo Transfer
NCT05638529	PHASE4	UNKNOWN	Dual Trigger in IVF Patients at High Risk of Ovarian Hyper Stimulation Syndrome
NCT05586802	PHASE3	RECRUITING	Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter Syndrome
NCT02739516	PHASE3	COMPLETED	Dual FSH/HCG Trigger in Letrozole Stimulated Intrauterine Insemination Cycles in Women With Unexplained Infertility
NCT04537078	PHASE3	COMPLETED	Progestin Primed Double Stimulation Protocol Versus Flexible GnRH Antagonist Protocol in Poor Responders
NCT06725004	PHASE3	COMPLETED	Oxytocin Versus Human Chorionic Gonadotropin as Trigger in Ovulation Induction
NCT02427529	PHASE1/PHASE2	COMPLETED	Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)
NCT04189133	PHASE2	UNKNOWN	Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men
NCT06754332	PHASE1	NOT_YET_RECRUITING	The Study of Human Chorionic Gonadotropin (HCG) Activating the Dormant Follicles .
NCT03418896	PHASE1	COMPLETED	Extragonadal Effects of hCG on Calcium Homeostasis
NCT02397642	Not specified	COMPLETED	Dual Trigger Versus Booster Dose of HCG
NCT02728440	Not specified	COMPLETED	Effects of Gonadotropin Replacement Therapy on Metabolic Parameters in Patients With Hypogonadism
NCT02788136	Not specified	COMPLETED	Human Chorionic Gonadotropin Stimulation Effects on Steroidogenesis in Men With Klinefelter Syndrome
NCT02940535	Not specified	UNKNOWN	Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response
NCT03238807	Not specified	COMPLETED	Effect of Intrauterine Injection of Hcg Before ET on Clinical Outcomes in IVF/ICSI Cycles
NCT03254641	Not specified	COMPLETED	Calciotropic Effects After HCG Stimulation Test
NCT03307720	Not specified	UNKNOWN	Agonist Versus Classical HCG Trigger (Poor Responders, Normoresponders and High Responders)
NCT03398993	Not specified	UNKNOWN	Effect of Endometrial Injury in Couples With Unexplained Infertility
NCT03445910	Not specified	COMPLETED	Intrauterine Injection of Human Chorionic Gonadotrophin and Pregnancy Rate in ICSI
NCT03484611	Not specified	UNKNOWN	Prediction of Metaphase II Oocytes According to Different Levels of Serum AMH in Poor Responders Using the Antagonist Protocol
NCT03904355	Not specified	UNKNOWN	Effects of Intramural Fibroids on IVF Outcome
NCT03904368	Not specified	UNKNOWN	The Value of Myomectomy in Women With Intramural Myoma Before IVF.
NCT05076981	Not specified	COMPLETED	Progesterone Levels During Ovulation and Luteal Phase
NCT05112692	Not specified	UNKNOWN	Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles
NCT05393011	Not specified	COMPLETED	Relationship Between Some Vitamins and Antioxidants With in Vitro Fertilization Outcomes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

14 molecules share ≥1 primary target. Top 14 by shared-target count:

Molecule	Source	Status	Shared targets
CETRORELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
DEGARELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
ELAGOLIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
GANIRELIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
RELUGOLIX	ChEMBL + PubChem	Phase 4 (approved)	GNRHR
ABARELIX	ChEMBL	Phase 4 (approved)	GNRHR
GONADORELIN	ChEMBL	Phase 4 (approved)	GNRHR
LEUPROLIDE	ChEMBL	Phase 4 (approved)	GNRHR
LINZAGOLIX	ChEMBL	Phase 4 (approved)	GNRHR
ACYLINE	ChEMBL	Phase 2	GNRHR
SUFUGOLIX	ChEMBL	Phase 2	GNRHR
Belzutifan	PubChem	Approved	GNRHR
Deslorelin	PubChem	Approved	GNRHR
Triptorelin	PubChem	Approved	GNRHR